The logistics of getting drugs delivered in underdeveloped countries can be tricky. Many companies turn to partners with the expertise that can help them navigate the import laws and distribution obstacles that those countries present.
Should taxpayers enjoy lower drug prices if federal money backed development? At least one U.S. senator thinks so, now that Pfizer has slapped a $2,000-per-month sticker price on the new rheumatoid arthritis drug Xeljanz.
The fight over drug patents in India is quickly ratcheting up even as other countries are looking at new twists on the model for getting their hands on cheaper drugs.
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
Mytrus has found a new patron as the startup advances mobile apps for clinical trials. InVentiv Health, a contract research organization (CRO) for pharma and device companies, has snapped up an equity stake in Mytrus and plans to partner on commercializing the startup's mobile apps.
Last year was a tough one for Pfizer ($PFE), having to shoulder a full 12 months without the riches of Lipitor to rely on. Still, CEO Ian Read did the best he could with what he had to work with. And for that, he got a small raise, although nothing like the 44% upgrade he received a year ago.
Lipitor as a loss leader? That's the approach Wegmans' pharmacies are taking. As the Philadelphia Inquirer reports, the grocery store chain offers generic versions of Lipitor for free, as a way to bring in new pharmacy customers. And the promotion must be successful--Wegmans just extended it through the end of this year.
Here we present the Top 5 vaccine companies based on their 2012 vaccine revenues, filtered out of company reports by EvaluatePharma. Take a look and let us know what you think. We always like to hear how you view and evaluate the data.
Doctors prescribe the "Z-Pak" for everything from ear infections to pneumonia. But the FDA wants to make clear that for a small group of people, there is a better than average chance it will mess with their heart rhythms and possibly kill them.
Two top research organizations have mounted a combined effort to discover new drugs for cancer, Alzheimer's disease and other illnesses.